We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Fig 2

Fig 2. From: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Kaplan-Meier analysis of time to death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs

Marie Hudson, et al. BMJ. 2005 June 11;330(7504):1370-1370.
2.
Fig 3

Fig 3. From: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Kaplan-Meier analysis of time to recurrent congestive heart failure in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs

Marie Hudson, et al. BMJ. 2005 June 11;330(7504):1370-1370.
3.
Fig 1

Fig 1. From: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Kaplan-Meier analysis of time to recurrent congestive heart failure or death in patients prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs

Marie Hudson, et al. BMJ. 2005 June 11;330(7504):1370-1370.
4.
Fig 4

Fig 4. From: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

Adjusted hazard ratios (95% confidence intervals) for death and recurrent congestive heart failure, combined and alone, according to exposure group

Marie Hudson, et al. BMJ. 2005 June 11;330(7504):1370-1370.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk